Similar articles

• Non-intravenous approaches to iron therapy in chronic kidney disease: will it improve the benefit-to-risk ratio?

  Besarab A. Besarab A. Nephrol News Issues. 2014 Feb;28(2):12, 14-5. Nephrol News Issues. 2014. PMID: 24649747 Review. No abstract available.
• Toxic effects of IV iron preparations in CKD patients.

  Vaziri ND. Vaziri ND. Nephrol News Issues. 2014 Feb;28(2):4-5. Nephrol News Issues. 2014. PMID: 24649744 Review.
• Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation.

  Vaziri ND. Vaziri ND. Am J Med. 2012 Oct;125(10):951-2. doi: 10.1016/j.amjmed.2012.02.009. Epub 2012 Jul 13. Am J Med. 2012. PMID: 22795817 No abstract available.
• Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis.

  Vaziri ND. Vaziri ND. Am J Kidney Dis. 2013 Jun;61(6):992-1000. doi: 10.1053/j.ajkd.2012.10.027. Epub 2013 Jan 31. Am J Kidney Dis. 2013. PMID: 23375852 Review.
• Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients.

  Kshirsagar AV, Li X. Kshirsagar AV, et al. Adv Chronic Kidney Dis. 2019 Jul;26(4):292-297. doi: 10.1053/j.ackd.2019.05.001. Adv Chronic Kidney Dis. 2019. PMID: 31477259 Review.